Michael Doherty has been Head of Product Development at Foundation Medicine since the beginning of 2017. In this role, he leads a team dedicated to the introduction of clinical and data products in the field of cancer genomics based on Next-Generation Sequencing.
Prior to this he was Head of Regulatory Affairs at Roche Pharmaceuticals and Genentech for a period of 14 years from 2002 to 2016, overseeing the approvals of products in the field of oncology, immunology, hematology and bone disease. During his career, he has worked in Regulatory Affairs in Pharmaceutical Companies based in the UK, France, Switzerland and the US.
In addition, he spent 2 years at Genentech building a new organization called Strategic Innovation which was charged with identifying and deploying disruptive concepts in the field of drug development.
Today, Michael also serves as a Strategic Adviser to Genentech Product Development and as a Regulatory Strategy Adviser to VisionGate, a clinical stage cancer diagnostics and therapeutics company. He also serves on the advisory board of IBM Watson Life Sciences.
Prior to working in the Pharmaceutical Industry, Michael worked at the University of Manchester, UK, and Christie Hospital in the Regional Endocrinology Laboratory. He has a BSc in Biochemistry (University of Reading, UK) and a fellowship of the Institute of Medical Sciences, UK, and a Diploma in Management Studies from the University of Portsmouth, UK.